More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment
Open Access
- 15 November 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (2), e298-e305
- https://doi.org/10.1002/onco.13595
Abstract
The NOTCH1 gene encodes a transmembrane receptor protein with activating mutations observed in many T‐cell acute lymphoblastic leukemias (T‐ALLs) and lymphomas, as well as in other tumor types, which has led to interest in inhibiting NOTCH1 signaling as a therapeutic target in cancer. Several classes of Notch inhibitors have been developed, including monoclonal antibodies against NOTCH receptors or ligands, decoys, blocking peptides, and γ‐secretase inhibitors (GSIs). GSIs block a critical proteolytic step in NOTCH activation and are the most widely studied. Current treatments with GSIs have not successfully passed clinical trials because of side effects that limit the maximum tolerable dose. Multiple γ‐secretase–cleavage substrates may be involved in carcinogenesis, indicating that there may be other targets for GSIs. Resistance mechanisms may include PTEN inactivation, mutations involving FBXW7, or constitutive MYC expression conferring independence from NOTCH1 inactivation. Recent studies have suggested that selective targeting γ‐secretase may offer an improved efficacy and toxicity profile over the effects caused by broad‐spectrum GSIs. Understanding the mechanism of GSI‐induced cell death and the ability to accurately identify patients based on the activity of the pathway will improve the response to GSI and support further investigation of such compounds for the rational design of anti‐NOTCH1 therapies for the treatment of T‐ALL. Implications for Practice γ‐secretase has been proposed as a therapeutic target in numerous human conditions, including cancer. A better understanding of the structure and function of the γ‐secretase inhibitor (GSI) would help to develop safe and effective γ‐secretase–based therapies. The ability to accurately identify patients based on the activity of the pathway could improve the response to GSI therapy for the treatment of cancer. Toward these ends, this study focused on γ‐secretase inhibitors as a potential therapeutic target for the design of anti‐NOTCH1 therapies for the treatment of T‐cell acute lymphoblastic leukemias and lymphomas.Keywords
Funding Information
- Agencia Estatal de Investigación (SAF2015-70561-R)
- Comunidad de Madrid (B2017/BMD-3778)
- Fundación Científica Asociación Española Contra el Cáncer (PROYE18054PIRI)
- Spanish Ministry of Science, Innovation and Universities (MCIU
- Ramón Areces Fundation (CIVP19S7917)
- Instituto de Salud Carlos III (ACCI-CIBERER-17)
This publication has 46 references indexed in Scilit:
- Therapeutic approaches to modulating Notch signaling: Current challenges and future prospectsSeminars in Cell & Developmental Biology, 2012
- Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemiaBritish Journal of Pharmacology, 2009
- Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal AdenocarcinomaGastroenterology, 2009
- Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancerProceedings of the National Academy of Sciences, 2009
- ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenesProceedings of the National Academy of Sciences of the United States of America, 2009
- Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemiaNature Medicine, 2007
- FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitorsThe Journal of Experimental Medicine, 2007
- Notch1 Contributes to Mouse T-Cell Leukemia by Directly Inducing the Expression of c-mycMolecular and Cellular Biology, 2006
- c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphomaGenes & Development, 2006
- NOTCH ANDPRESENILIN: Regulated Intramembrane Proteolysis Links Development and DegenerationAnnual Review of Neuroscience, 2003